3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
2
Endocrine
2
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Colorectal Neoplasms
9
Neoplasm Metastasis
4
Sarcoma
3
Pancreatic Neoplasms
3
Lymphoma, Non-Hodgkin
3
Glioma
3
Breast Neoplasms
3
Wilms Tumor
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Neoplasms
2
Multiple Myeloma
2
Melanoma
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Hematologic Neoplasms
2
Ependymoma
2
Colorectal Cancer Metastatic
2
Central Nervous System Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Xanthogranuloma, Juvenile
1
Urinary Bladder Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Interventions
trametinib
2
dabrafenib
2
Trastuzumab
2
zimberelimab
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
tislelizumab
1
tipifarnib
1
surufatinib
1
sargramostim
1
mercaptoundecahydrododecaborate
1
cobimetinib
1
aldesleukin
1
Vemurafenib
1
Tamoxifen
1
Radiotherapy
1
PLX8394
1
Interleukin-12 Subunit p35
1
Interleukin-12
1
Doxorubicin
1
Cisplatin
1
4-boronophenylalanine-fructose
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thyroid Carcinoma, Anaplastic
×
Vemurafenib
×
Gastrointestinal
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled